Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 6:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 36 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: 129Xe MRI Clear all
Active, not recruiting No phase listed Observational

Monitoring Response to Orkambi in Cystic Fibrosis Lung Disease by Inhaled Xenon MRI

NCT02848560
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Hyperpolarized Xenon
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years to 12 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Sep 2, 2026, 6:32 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Hyperpolarized Xenon-129 Magnetic Resonance Imaging and Spectroscopy of Brown Fat: Healthy Adult Volunteer Pilot Study

NCT02220426
View directory record Official record
Conditions
Obesity
Interventions
Xenon
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 60 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Sep 2, 2026, 6:32 AM EDT
Completed Phase 2 Interventional Results available

Assessing Response to Inhaled Prostacyclin With Hyperpolarized Xe MRI

NCT03367312
View directory record Official record
Conditions
Pulmonary Vascular Disease
Interventions
Hyperpolarized 129Xenon gas
Drug
Lead sponsor
Bastiaan Driehuys
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 17, 2023 · Synced Sep 2, 2026, 6:32 AM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Functional Applications of Hyperpolarized 129Xe MRI

NCT01697332
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Hyperpolarized 129Xe gas
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
20 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 16, 2018 · Synced Sep 2, 2026, 6:32 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

129Xe MRI Cardiopulmonary

NCT06038630
View directory record Official record
Conditions
Interstitial Lung Disease, Chronic Thromboembolic Pulmonary Hypertension, Acute Pulmonary Embolism, Anemia, Polycythemia, Dyspnea
Interventions
Hyperpolarized Xe129, Oxygen Administration
Drug · Other
Lead sponsor
Bastiaan Driehuys
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Sep 2, 2026, 6:32 AM EDT
Completed Phase 3 Interventional

Hyperpolarized Xenon MRI for Assessment of Pulmonary Function in Lung Transplant

NCT03418090
View directory record Official record
Conditions
Pulmonary Surgical Procedures
Interventions
129Xe MRI, 133XE scintigraphy
Drug
Lead sponsor
Polarean, Inc.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Durham, North Carolina • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Sep 2, 2026, 6:32 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Regional Phenotyping of CF and Non-CF Bronchiectasis

NCT04793867
View directory record Official record
Conditions
Cystic Fibrosis, Non-CF Bronchiectasis
Interventions
Xenon
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
5 Years to 100 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Sep 2, 2026, 6:32 AM EDT
Recruiting Phase 2 Interventional

129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH)

NCT06104228
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Idiopathic Pulmonary Arterial Hypertension, Pulmonary Arterial Hypertension Associated With Connective Tissue Disease (Disorder), Connective Tissue Diseases
Interventions
129Xe Hyperpolarized
Drug
Lead sponsor
Bastiaan Driehuys
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Sep 2, 2026, 6:32 AM EDT
Recruiting Phase 4 Interventional

Improving Outcomes in Pediatric Obstructive Sleep Apnea With Computational Fluid Dynamics

NCT04991389
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
129-Xe
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
3 Years to 18 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Sep 2, 2026, 6:32 AM EDT
Completed Phase 2 Interventional Results available

Dual MRI for Cardiopulmonary COVID-19 Long Haulers

NCT04828135
View directory record Official record
Conditions
Covid19
Interventions
Hyperpolarized 129Xenon gas
Drug
Lead sponsor
Bastiaan Driehuys
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 5, 2024 · Synced Sep 2, 2026, 6:32 AM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Non-contrast Lung Perfusion Mapping Applied for New Insights in Cystic Fibrosis

NCT04467957
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Initiation of CFTR Modulator, Hyperpolarized Xenon 129
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years to 21 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Sep 2, 2026, 6:32 AM EDT
Completed Phase 1 Interventional

Hyperpolarized 129Xe MRI of Survivors of COVID-19

NCT04659707
View directory record Official record
Conditions
Covid19
Interventions
Hyperpolarized Xe129
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Sep 2, 2026, 6:32 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Chronic Lung Allograft Dysfunction MRI Study

NCT06406777
View directory record Official record
Conditions
Chronic Lung Allograft Dysfunction Lung MRI (CLAD)
Interventions
Spirometry, Contrast Lung Computed Tomography (CT) Scan, Oxygen enhanced magnetic resonance imaging (OE-MRI) Scan, 129Xe MRI scans
Diagnostic Test · Drug
Lead sponsor
Sean Fain
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 2, 2026, 6:32 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Hyperpolarized 129Xe MRI for Imaging Pulmonary Function

NCT01280994
View directory record Official record
Conditions
Interstitial Lung Disease
Interventions
Hyperpolarized 129Xenon Gas
Drug
Lead sponsor
Bastiaan Driehuys
Other
Eligibility
18 Years and older
Enrollment
445 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2030
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Sep 2, 2026, 6:32 AM EDT
Recruiting Phase 4 Interventional

BEGIN Novel ImagiNG Biomarkers

NCT05517655
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
129Xe
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years to 8 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
3
States / cities
Kansas City, Kansas • Cincinnati, Ohio • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Sep 2, 2026, 6:32 AM EDT
Recruiting No phase listed Observational

Hyperpolarized 129Xe MRI Lung Health Cohort

NCT05766384
View directory record Official record
Conditions
Healthy
Interventions
Hyperpolarized Xe129
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
25 Years to 35 Years
Enrollment
260 participants
Timeline
2023 – 2027
U.S. locations
6
States / cities
Chicago, Illinois • Iowa City, Iowa • Kansas City, Kansas + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Sep 2, 2026, 6:32 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigating Radiation-response and Toxicity

NCT06909201
View directory record Official record
Conditions
Lung Cancer
Interventions
HP 129Xe MRI
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 2, 2026, 6:32 AM EDT
Recruiting Phase 2 Interventional

129 Xenon Imaging in Patients Treated With Sotatercept

NCT06351345
View directory record Official record
Conditions
Pulmonary Hypertension, Pulmonary Arterial Hypertension
Interventions
129Xe Hyperpolarized
Drug
Lead sponsor
Bastiaan Driehuys
Other
Eligibility
18 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Sep 2, 2026, 6:32 AM EDT
Completed Phase 3 Interventional Results available

Hyperpolarized Xenon MRI for Assessment of Pulmonary Function in Lung Resection

NCT03417687
View directory record Official record
Conditions
Pulmonary Surgical Procedures
Interventions
129Xe MRI, 133 Xe scintigraphy
Drug
Lead sponsor
Polarean, Inc.
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
3
States / cities
Durham, North Carolina • Cincinnati, Ohio • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 27, 2022 · Synced Sep 2, 2026, 6:32 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Longitudinal MR Imaging of Pulmonary Function in Patients Receiving Thoracic Radiation Treatment

NCT02478255
View directory record Official record
Conditions
Radiation Injury
Interventions
Hyperpolarized 129-Xenon gas, MRI
Drug · Device
Lead sponsor
Bastiaan Driehuys
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 16, 2023 · Synced Sep 2, 2026, 6:32 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Effects of Bevespi on Ventilation and Gas Exchange Abnormalities in COPD Assessed by 129Xe MRI

NCT03324607
View directory record Official record
Conditions
COPD
Interventions
hyperpolarized 129Xe gas MRI, Bevespi Aerosphere
Drug
Lead sponsor
Bastiaan Driehuys
Other
Eligibility
40 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 18, 2021 · Synced Sep 2, 2026, 6:32 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Comparison of 129Xe MRI With 19F MRI in CF Lung Disease

NCT03482960
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Hyperpolarized Xenon gas, PFP
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 24, 2021 · Synced Sep 2, 2026, 6:32 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Optimizing and Standardizing 129Xe Gas Exchange MRI to Visualize Regional Therapy Response in Interstitial Lung Disease

NCT04855305
View directory record Official record
Conditions
Interstitial Lung Diseases
Interventions
Hyperpolarized 129Xe
Drug
Lead sponsor
Bastiaan Driehuys
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Sep 2, 2026, 6:32 AM EDT
Completed Phase 2 Interventional Results available

Non-Invasive Diagnosis of Pulmonary Vascular Disease Using Inhaled 129Xe Magnetic Resonance Imaging

NCT03078192
View directory record Official record
Conditions
Pulmonary Vascular Disease
Interventions
GE-141, Hyperpolarized 129Xenon gas, MRI
Drug · Device
Lead sponsor
Bastiaan Driehuys
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 21, 2022 · Synced Sep 2, 2026, 6:32 AM EDT